- Home
- ACR vs CNTX Comparison
ACR vs CNTX Comparison
Compare ACR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACR
- CNTX
- Stock Information
- Founded
- ACR 2005
- CNTX 2015
- Country
- ACR United States
- CNTX United States
- Employees
- ACR N/A
- CNTX N/A
- Industry
- ACR Real Estate Investment Trusts
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACR Real Estate
- CNTX Health Care
- Exchange
- ACR Nasdaq
- CNTX Nasdaq
- Market Cap
- ACR 127.9M
- CNTX 149.6M
- IPO Year
- ACR N/A
- CNTX 2021
- Fundamental
- Price
- ACR $16.78
- CNTX $1.84
- Analyst Decision
- ACR Buy
- CNTX Strong Buy
- Analyst Count
- ACR 2
- CNTX 3
- Target Price
- ACR $17.50
- CNTX $6.83
- AVG Volume (30 Days)
- ACR 23.4K
- CNTX 318.3K
- Earning Date
- ACR 10-30-2024
- CNTX 11-06-2024
- Dividend Yield
- ACR N/A
- CNTX N/A
- EPS Growth
- ACR N/A
- CNTX N/A
- EPS
- ACR 0.83
- CNTX N/A
- Revenue
- ACR $77,437,000.00
- CNTX N/A
- Revenue This Year
- ACR N/A
- CNTX N/A
- Revenue Next Year
- ACR N/A
- CNTX N/A
- P/E Ratio
- ACR $20.12
- CNTX N/A
- Revenue Growth
- ACR 8.77
- CNTX N/A
- 52 Week Low
- ACR $7.31
- CNTX $0.77
- 52 Week High
- ACR $16.93
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- ACR 69.69
- CNTX 37.02
- Support Level
- ACR $16.00
- CNTX $1.90
- Resistance Level
- ACR $16.93
- CNTX $2.32
- Average True Range (ATR)
- ACR 0.33
- CNTX 0.14
- MACD
- ACR 0.11
- CNTX -0.04
- Stochastic Oscillator
- ACR 92.72
- CNTX 9.80
About ACR ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.